Avidity biosciences, inc. announces proposed public offering of common stock

San diego , dec. 15, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it intends to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. in addition, avidity intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
RNA Ratings Summary
RNA Quant Ranking